(IN BRIEF) AstraZeneca has unveiled data from four pivotal Phase III trials at the European Society for Medical Oncology (ESMO) Congress, demonstrating advances in cancer treatments across multiple types of cancers. These trials include TROPION-Lung01 and TROPION-Breast01, showcasing the significance … Read the full press release
Posted in Business, Education, Healthcare, Industrial, Management, Media, News, Pharma & Biotech, Science, Technology, United Kingdom
Tagged AstraZeneca, breast cancer, cancer treatments, datopotamab deruxtecan, Dave Fredrickson, DESTINY-PanTumor02, DUO-E, ESMO Congress, FLAURA2, gastrointestinal cancer, Imfinzi, lung cancer, MATTERHORN, Phase III Trials, Susan Galbraith, Tagrisso, TROPION-Breast01, TROPION-Lung01
(IN BRIEF) Roche has announced positive late-breaking data from the Phase III OCARINA II study, which demonstrates the effectiveness of OCREVUS as a twice-yearly, 10-minute subcutaneous injection for patients with relapsing or primary progressive multiple sclerosis (RMS or PPMS). The … Read the full press release
(IN BRIEF) Merck has presented new data on evobrutinib, an investigational BTK inhibitor, at the 9th Joint ECTRIMS-ACTRIMS congress. The data from an ongoing Phase II open-label extension study of evobrutinib in patients with relapsing multiple sclerosis (RMS) show sustained … Read the full press release
Posted in Business, Education, Germany, Healthcare, Industrial, Management, News, Pharma & Biotech, Science
Tagged BTKi, Evobrutinib, Jan Klatt, Merck, multiple sclerosis, relapsing multiple sclerosis (RMS), treatment
(IN BRIEF) GlaxoSmithKline (GSK) has announced a confidential settlement in the Cantlay/Harper case filed in California state court, which was scheduled for trial in November 2023. Additionally, GSK has settled the three remaining breast cancer bellwether cases in California, effectively … Read the full press release
Posted in Business, Government, Healthcare, Industrial, Law, Management, News, Pharma & Biotech, Science, United Kingdom
Tagged breast cancer, California, Confidential Settlements, GSK, litigation, Zantac
(IN BRIEF) Merck, a prominent science and technology company, has revealed new findings from the MAVENCLAD® (cladribine tablets) MAGNIFY-MS study at the 9th Joint ECTRIMS-ACTRIMS meeting in Milan. The study demonstrated that patients with relapsing multiple sclerosis (RMS) experienced a … Read the full press release
Posted in Business, Germany, Healthcare, Industrial, Management, News, Pharma & Biotech, Science
Tagged Alexander Kulla, MAVENCLAD, Merck, multiple sclerosis, Neuronal Injury, reduction
(IN BRIEF) Almirall, a global biopharmaceutical company specializing in medical dermatology, has entered into an agreement with Centrient Pharmaceuticals, a leader in sustainable biosynthetic pharmaceuticals, to establish a dedicated innovation lab at Almirall’s R&D center in Sant Feliu de Llobregat, … Read the full press release
Posted in Business, Education, Environment, Financial, Healthcare, Industrial, Infrastructure & Utilities, Investment, Management, Netherlands, News, Pharma & Biotech, Science, Spain, Technology
Tagged Almirall, Barcelona, Centrient Pharmaceuticals, Innovation Lab, Jorge Gil-Martinez, Karl Ziegelbauer, medical dermatology, partnership, R&D center, Rex Clements, sustainability
(IN BRIEF) Bayer has invested $250 million in a new cell therapy production plant in Berkeley, California, USA. This investment aims to support the production of materials for clinical trials and potential commercial launches of BlueRock Therapeutics’ bemdaneprocel (BRT-DA01), an … Read the full press release
Posted in Business, Environment, Financial, Germany, Government, Healthcare, Industrial, Infrastructure & Utilities, Investment, Management, News, Pharma & Biotech, Science
Tagged Bayer, Bemdaneprocel, Berkeley, BRT-DA01, California, Cell Therapy Plant, Holger Weintritt, Parkinson's disease, partnership, Seth Ettenberg, Stefan Oelrich, sustainability, USA
(IN BRIEF) Fujirebio Holdings and Sysmex Corporation have entered into a Basic Agreement on Business Collaboration in the field of immunoassay. This collaboration will involve various aspects such as research and development, production, clinical development, and sales-marketing. Sysmex, known for … Read the full press release
Posted in Belgium, Business, Education, Environment, Financial, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Technology
Tagged Fujirebio, Goki Ishikawa, Immunoassay Technology, partnership, sustainability, Sysmex
(IN BRIEF) Eni CEO Claudio Descalzi and Dompé farmaceutici Executive Chairman Sergio Dompé have signed a Letter of Intent to initiate joint research and development efforts focused on public health and community well-being in regions where Eni operates, along with … Read the full press release
(IN BRIEF) GSK plc has announced an exclusive agreement with Chongqing Zhifei Biological Products, Ltd. (Zhifei) to co-promote GSK’s shingles vaccine, Shingrix, in China for an initial three-year period, with the potential for extension. Zhifei, China’s largest vaccine company by … Read the full press release
Posted in Business, Financial, Government, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, United Kingdom
Tagged CHINA, GSK, Luke Miels, partnership, Shingles, Shingrix Vaccine, Zhifei
(IN BRIEF) Merck, a prominent science and technology company, has entered into a collaboration with the United Nations’ Global Initiative on Ageing (GIA) to offer a training course aimed at equipping family carers with essential skills. The course comprises five … Read the full press release
Posted in Business, Education, Germany, Healthcare, Industrial, Management, Media, News, Pharma & Biotech, Science
Tagged caregivers, Embracing Carers®, European Carers Day, Family Carers, Global Initiative on Ageing (GIA), Luis Gallegos, Merck, partnership, Peter Guenter, training course, United Nations
(IN BRIEF) Roche has reported positive outcomes from the RAINBOWFISH study, an investigation into the efficacy and safety of Evrysdi® (risdiplam) in babies with pre-symptomatic spinal muscular atrophy (SMA). The study, which included 26 infants aged from birth to six … Read the full press release
Posted in Business, Environment, Financial, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Switzerland
Tagged Evrysdi, Levi Garraway, Pre-Symptomatic SMA Babies, RAINBOWFISH study, Richard Finkel, Roche, wellness
(IN BRIEF) Sanofi and Teva Pharmaceuticals have announced a collaboration to co-develop and co-commercialize TEV’574, a promising asset currently in Phase 2b clinical trials for the treatment of Ulcerative Colitis and Crohn’s Disease, both forms of inflammatory bowel disease (IBD). … Read the full press release
Posted in Business, Environment, Financial, France, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science
Tagged Anti-TL1As, Crohn's disease, in $1.5 Billion Deal, Inflammatory Bowel Disease Treatment, partnership, Paul Hudson, Richard Francis, Sanofi, sustainability, Teva, TEV’574, Ulcerative colitis, wellness
(IN BRIEF) Sandoz Group AG, a Novartis spin-off, officially listed its shares at the SIX Swiss Exchange. With an opening share price of CHF 24.00, the market capitalization of Sandoz reached approximately CHF 10.3 billion. Sandoz’s issued share capital consists … Read the full press release
Posted in Business, Financial, Industrial, Investment, Management, News, Pharma & Biotech, Switzerland
Tagged Financial, investment, Jos Dijsselhof, Novartis, partnership, Richard Saynor, Sandoz Group, shares, SIX Swiss Exchange
(IN BRIEF) Sanofi has entered into an agreement with Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson, to develop and commercialize a vaccine candidate for extraintestinal pathogenic E. coli (ExPEC) that is currently in Phase 3 of clinical trials. ExPEC … Read the full press release
Posted in Business, Financial, France, Government, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science
Tagged E. coli, E.mbrace, ExPEC, Janssen, partnership, Sanofi, SEPSIS, sustainability, Thomas Triomphe, vaccine
(IN BRIEF) The University of Oxford’s R21/Matrix-M™ malaria vaccine, developed in collaboration with the Serum Institute of India and leveraging Novavax’s adjuvant technology, has received a recommendation for use by the World Health Organization (WHO). After rigorous scientific review by … Read the full press release
Posted in Business, Education, Environment, Government, Healthcare, Industrial, Management, News, Non Profit, Pharma & Biotech, Science, United Kingdom
Tagged Adar Poonawalla, CHILDREN, Dr Lisa Stockdale, Dr Mehreen Datoo, John C. Jacobs, malaria vaccine, Novavax, partnership, Professor Sir Adrian Hill, R21/Matrix-M™, Serum Institute of India, sustainability, University of Oxford, World Health Organization
(IN BRIEF) The European Investment Bank (EIB) has signed a €10 million loan agreement with Polish company SDS Optic Inc. to support the development and commercialization of their innovative cancer detection technology platform, inPROBE®. SDS Optic specializes in diagnostic and … Read the full press release
Posted in Banks, European Union, Financial, Healthcare, Pharma & Biotech, Poland, Science, Technology
Tagged advanced photonic technologies, biomedical engineering, breast cancer, breast cancer detection device, cancer detection technology, diagnostics, EIB, immunochemistry, inPROBE®, inPROBE® HER2, InvestEU programme, loan, Marcin Staniszewski, Molecular Biology, monitoring devices, Paolo Gentiloni, photonic biosensing, Prof. Teresa Czerwińska, SDS Optic Inc., single cell resolution immunoassay, The European Investment Bank, Warsaw Stock Exchange
(IN BRIEF) GSK plc has received approval from Japan’s Ministry of Health, Labour and Welfare (MHLW) for its Arexvy (respiratory syncytial virus vaccine, recombinant adjuvanted) to prevent respiratory syncytial virus (RSV) disease in adults aged 60 and above. This marks … Read the full press release
Posted in Business, Financial, Government, Healthcare, Industrial, Investment, Management, Marketing, News, Pharma & Biotech, Science, Technology, United Kingdom
Tagged Adults Aged 60 and Above, AReSVi-006, Arexvy, GSK, Japan, RSV Vaccine, Tony Wood, wellness
(IN BRIEF) The Japanese Ministry of Health, Labor, and Welfare (MHLW) has granted marketing authorization for ALTUVIIIO, a novel factor VIII replacement therapy used to control bleeding in patients with hemophilia A. ALTUVIIIO, also known as efanesoctocog alfa, stands out … Read the full press release
Posted in Business, Financial, France, Government, Healthcare, Industrial, Investment, Management, Marketing, News, Pharma & Biotech, Science
Tagged ALTUVIIIO, authorization, bleeding, Brian Foard, efanesoctocog alfa, FDA, hemophilia A, Japan, marketing, MHLW, partnership, Sanofi, Sobi, treatment
(IN BRIEF) Novartis has announced successful results from its Phase III NETTER-2 trial involving Lutathera, a treatment for neuroendocrine tumors (NETs). When used as a first-line treatment in combination with long-acting octreotide, Lutathera significantly improved progression-free survival in patients with … Read the full press release
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions. Here you can learn more about EuropaWire’s mission, achievements, services, etc.
HOW TO GET STARTED?